{
    "xml": "<topic id=\"PHP4161\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/metformin-hydrochloride\" basename=\"metformin-hydrochloride\" title=\"METFORMIN HYDROCHLORIDE\">\n<title>METFORMIN HYDROCHLORIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_267\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/biguanides/metformin\">Metformin</xref>\n</p>\n<data name=\"vtmid\">109081006</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_709441655\" title=\"Biguanides\">Biguanides</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP45167\" outputclass=\"drugAction\" rev=\"1.7\" parent=\"/drugs/metformin-hydrochloride\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Metformin exerts its effect mainly by decreasing gluconeogenesis and by increasing peripheral utilisation of glucose; since it acts only in the presence of endogenous insulin it is effective only if there are some residual functioning pancreatic islet cells.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44732\" outputclass=\"indicationsAndDose\" rev=\"1.46\" parent=\"/drugs/metformin-hydrochloride\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Diabetes mellitus</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth using immediate-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 10&#8211;17 years (specialist use only)</p>\n<p>Initially 500&#8239;mg once daily, dose to be adjusted according to response at intervals of at least 1 week, maximum daily dose to be given in 2&#8211;3 divided doses; maximum 2&#8239;g per day.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 500&#8239;mg once daily for at least 1 week, dose to be taken with breakfast, then 500&#8239;mg twice daily for at least 1 week, dose to be taken with breakfast and evening meal, then 500&#8239;mg 3 times a day, dose to be taken with breakfast, lunch and evening meal; maximum 2&#8239;g per day.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By mouth using modified-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 500&#8239;mg once daily, then increased if necessary up to 2&#8239;g once daily, dose increased gradually, every 10&#8211;15&#8239;days, dose to be taken with evening meal, alternatively increased to 1&#8239;g twice daily, dose to be taken with meals, alternative dose only to be used if control not achieved with once daily dose regimen. If control still not achieved then change to standard release tablets.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Polycystic ovary syndrome</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth using immediate-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 500&#8239;mg once daily for 1 week, dose to be taken with breakfast, then 500&#8239;mg twice daily for 1 week, dose to be taken with breakfast and evening meal, then 1.5&#8211;1.7&#8239;g daily in 2&#8211;3 divided doses.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43847\" outputclass=\"unlicensedUse\" rev=\"1.12\" parent=\"/drugs/metformin-hydrochloride\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p>Doses in the BNF may differ from those in the product literature.</p>\n<p>Not licensed for polycystic ovary syndrome.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>Not licensed for use in children under 10 years.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45612\" outputclass=\"contraindications\" rev=\"1.9\" parent=\"/drugs/metformin-hydrochloride\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Ketoacidosis</ph>; <ph outputclass=\"contraindication\">use of general anaesthesia (suspend metformin on the morning of surgery and restart when renal function returns to baseline)</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Contra-indications, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Iodine-containing X-ray contrast media</p>\n<p>Intravascular administration of iodinated contrast agents can cause renal failure, which can increase the risk of lactic acidosis with metformin. Suspend metformin prior to the test; restart no earlier than 48 hours after the test if renal function has returned to baseline.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46039\" outputclass=\"cautions\" rev=\"1.10\" parent=\"/drugs/metformin-hydrochloride\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Can provoke lactic acidosis</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44641\" outputclass=\"interactions\" rev=\"1.6\" parent=\"/drugs/metformin-hydrochloride\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (antidiabetics).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44069\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/metformin-hydrochloride\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">anorexia</ph>; <ph outputclass=\"sideEffect\">diarrhoea (usually transient)</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">taste disturbance</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Decreased vitamin-B<sub>12</sub> absorption</ph>; <ph outputclass=\"sideEffect\">erythema</ph>; <ph outputclass=\"sideEffect\">lactic acidosis (withdraw treatment)</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">urticaria</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hepatitis</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Gastro-intestinal effects</p>\n<p>Gastro-intestinal side-effects are initially common with metformin, and may persist in some patients, particularly when very high doses are given. A slow increase in dose may improve tolerability.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44472\" outputclass=\"pregnancy\" parent=\"/drugs/metformin-hydrochloride\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Can be used in pregnancy for both pre-existing and gestational diabetes. Women with gestational diabetes should discontinue treatment after giving birth.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP46183\" outputclass=\"breastFeeding\" parent=\"/drugs/metformin-hydrochloride\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>May be used during breast-feeding in women with pre-existing diabetes.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44934\" outputclass=\"hepaticImpairment\" parent=\"/drugs/metformin-hydrochloride\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Withdraw if tissue hypoxia likely.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44193\" outputclass=\"renalImpairment\" parent=\"/drugs/metformin-hydrochloride\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use with caution in renal impairment&#8212; increased risk of lactic acidosis.</p>\n<sectiondiv>\n<p outputclass=\"title\">Lactic acidosis</p>\n<p>Withdraw or interrupt treatment in those at risk of tissue hypoxia or sudden deterioration in renal function, such as those with dehydration, severe infection, shock, sepsis, acute heart failure, respiratory failure or hepatic impairment, or those who have recently had a myocardial infarction.</p>\n</sectiondiv>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p>NICE (clinical guideline 87 (May 2009): Type 2 diabetes: The management of type 2 diabetes) recommends that the dose should be reviewed if eGFR less than 45&#8239;mL/minute/1.73&#8239;m<sup>2</sup> and to avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>Avoid in significant renal impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43793\" outputclass=\"monitoringRequirements\" parent=\"/drugs/metformin-hydrochloride\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Determine renal function before treatment and at least annually (at least twice a year in patients with additional risk factors for renal impairment, or if deterioration suspected).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP58895\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.9\" parent=\"/drugs/metformin-hydrochloride\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p>Patients taking up to 2&#8239;g daily of the standard-release metformin may start with the same daily dose of metformin modified release; not suitable if dose of standard-release tablets more than 2&#8239;g daily.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44373\" outputclass=\"patientAndCarerAdvice\" rev=\"1.17\" parent=\"/drugs/metformin-hydrochloride\">\n<title>Patient and carer advice</title>\n<body>\r\n\r\n\r\n<section outputclass=\"patientResources\">\r\n<sectiondiv>\r\n<p outputclass=\"specificity\">In children</p>\r\n<p outputclass=\"title\">Medicines for Children leaflet: Metformin for diabetes</p>\r\n<p>\n<xref format=\"html\" href=\"http://www.medicinesforchildren.org.uk/metformin-diabetes\">www.medicinesforchildren.org.uk/metformin-diabetes</xref>\n</p>\n</sectiondiv>\n</section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP4161-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/metformin-hydrochloride\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension, oral solution, capsule</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76109\" title=\"Tablet\" namespace=\"/drugs/metformin-hydrochloride/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76129\" title=\"Modified-release tablet\" namespace=\"/drugs/metformin-hydrochloride/modified-release-tablet\">Modified-release tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76123\" title=\"Oral solution\" namespace=\"/drugs/metformin-hydrochloride/oral-solution\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76135\" title=\"Powder\" namespace=\"/drugs/metformin-hydrochloride/powder\">Powder</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP101223\" namespace=\"/drugs/canagliflozin-with-metformin\" title=\"CANAGLIFLOZIN WITH METFORMIN\" count=\"1\" rel=\"backlink\">CANAGLIFLOZIN WITH METFORMIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85567\" namespace=\"/drugs/alogliptin-with-metformin\" title=\"ALOGLIPTIN WITH METFORMIN\" count=\"1\" rel=\"backlink\">ALOGLIPTIN WITH METFORMIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85589\" namespace=\"/drugs/dapagliflozin-with-metformin\" title=\"DAPAGLIFLOZIN WITH METFORMIN\" count=\"1\" rel=\"backlink\">DAPAGLIFLOZIN WITH METFORMIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85624\" namespace=\"/drugs/linagliptin-with-metformin\" title=\"LINAGLIPTIN WITH METFORMIN\" count=\"1\" rel=\"backlink\">LINAGLIPTIN WITH METFORMIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85626\" namespace=\"/drugs/metformin-with-pioglitazone\" title=\"METFORMIN WITH PIOGLITAZONE\" count=\"1\" rel=\"backlink\">METFORMIN WITH PIOGLITAZONE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85627\" namespace=\"/drugs/metformin-with-saxagliptin\" title=\"METFORMIN WITH SAXAGLIPTIN\" count=\"1\" rel=\"backlink\">METFORMIN WITH SAXAGLIPTIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85628\" namespace=\"/drugs/metformin-with-sitagliptin\" title=\"METFORMIN WITH SITAGLIPTIN\" count=\"1\" rel=\"backlink\">METFORMIN WITH SITAGLIPTIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85629\" namespace=\"/drugs/metformin-with-vildagliptin\" title=\"METFORMIN WITH VILDAGLIPTIN\" count=\"1\" rel=\"backlink\">METFORMIN WITH VILDAGLIPTIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP97237\" namespace=\"/guidance/adverse-reactions-to-drugs\" title=\"Adverse reactions to drugs\" count=\"1\" rel=\"backlink\">Adverse reactions to drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78083\" namespace=\"/treatment-summaries/scalp-and-hair-conditions\" title=\"Scalp and hair conditions\" count=\"1\" rel=\"backlink\">Scalp and hair conditions</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78107\" namespace=\"/treatment-summaries/insulins-and-anti-diabetic-drugs\" title=\"Insulins and anti-diabetic drugs\" count=\"41\" rel=\"backlink\">Insulins and anti-diabetic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_267\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/biguanides/metformin\" title=\"Metformin\" count=\"1\" rel=\"link\">Metformin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76109\" namespace=\"/drugs/metformin-hydrochloride/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76129\" namespace=\"/drugs/metformin-hydrochloride/modified-release-tablet\" title=\"Modified-release tablet\" count=\"1\" rel=\"link\">Modified-release tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76123\" namespace=\"/drugs/metformin-hydrochloride/oral-solution\" title=\"Oral solution\" count=\"1\" rel=\"link\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76135\" namespace=\"/drugs/metformin-hydrochloride/powder\" title=\"Powder\" count=\"1\" rel=\"link\">Powder</xref>\n</links>\n</topic>",
    "id": "PHP4161",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/metformin-hydrochloride",
    "basename": "metformin-hydrochloride",
    "title": "METFORMIN HYDROCHLORIDE",
    "interactants": [
        {
            "id": "bnf_int_267",
            "label": "Metformin"
        }
    ],
    "vtmid": "109081006",
    "drugClassification": [
        "Biguanides"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Metformin exerts its effect mainly by decreasing gluconeogenesis and by increasing peripheral utilisation of glucose; since it acts only in the presence of endogenous insulin it is effective only if there are some residual functioning pancreatic islet cells.",
                "html": "<p>Metformin exerts its effect mainly by decreasing gluconeogenesis and by increasing peripheral utilisation of glucose; since it acts only in the presence of endogenous insulin it is effective only if there are some residual functioning pancreatic islet cells.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Diabetes mellitus",
                        "html": "Diabetes mellitus"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using modified-release medicines"
                    ],
                    "textContent": "By mouth using modified-release medicines",
                    "html": "By mouth using modified-release medicines"
                },
                "child": [
                    {
                        "textContent": "Initially 500 mg once daily, dose to be adjusted according to response at intervals of at least 1 week, maximum daily dose to be given in 2&#8211;3 divided doses; maximum 2 g per day.",
                        "html": "<p>Initially 500&#8239;mg once daily, dose to be adjusted according to response at intervals of at least 1 week, maximum daily dose to be given in 2&#8211;3 divided doses; maximum 2&#8239;g per day.</p>",
                        "ageGroup": "10&#8211;17 years (specialist use only)"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Initially 500 mg once daily for at least 1 week, dose to be taken with breakfast, then 500 mg twice daily for at least 1 week, dose to be taken with breakfast and evening meal, then 500 mg 3 times a day, dose to be taken with breakfast, lunch and evening meal; maximum 2 g per day.",
                        "html": "<p>Initially 500&#8239;mg once daily for at least 1 week, dose to be taken with breakfast, then 500&#8239;mg twice daily for at least 1 week, dose to be taken with breakfast and evening meal, then 500&#8239;mg 3 times a day, dose to be taken with breakfast, lunch and evening meal; maximum 2&#8239;g per day.</p>"
                    },
                    {
                        "textContent": "Initially 500 mg once daily, then increased if necessary up to 2 g once daily, dose increased gradually, every 10&#8211;15 days, dose to be taken with evening meal, alternatively increased to 1 g twice daily, dose to be taken with meals, alternative dose only to be used if control not achieved with once daily dose regimen. If control still not achieved then change to standard release tablets.",
                        "html": "<p>Initially 500&#8239;mg once daily, then increased if necessary up to 2&#8239;g once daily, dose increased gradually, every 10&#8211;15&#8239;days, dose to be taken with evening meal, alternatively increased to 1&#8239;g twice daily, dose to be taken with meals, alternative dose only to be used if control not achieved with once daily dose regimen. If control still not achieved then change to standard release tablets.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Polycystic ovary syndrome",
                        "html": "Polycystic ovary syndrome"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using immediate-release medicines"
                    ],
                    "textContent": "By mouth using immediate-release medicines",
                    "html": "By mouth using immediate-release medicines"
                },
                "adult": [
                    {
                        "textContent": "Initially 500 mg once daily for 1 week, dose to be taken with breakfast, then 500 mg twice daily for 1 week, dose to be taken with breakfast and evening meal, then 1.5&#8211;1.7 g daily in 2&#8211;3 divided doses.",
                        "html": "<p>Initially 500&#8239;mg once daily for 1 week, dose to be taken with breakfast, then 500&#8239;mg twice daily for 1 week, dose to be taken with breakfast and evening meal, then 1.5&#8211;1.7&#8239;g daily in 2&#8211;3 divided doses.</p>"
                    }
                ]
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "textContent": "Doses in the BNF may differ from those in the product literature.\n\nNot licensed for polycystic ovary syndrome.",
                "html": "<p>Doses in the BNF may differ from those in the product literature.</p><p>Not licensed for polycystic ovary syndrome.</p>"
            },
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "Not licensed for use in children under 10 years.",
                "html": "<p>Not licensed for use in children under 10 years.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Ketoacidosis",
                "html": "Ketoacidosis"
            },
            {
                "type": "contraindications",
                "textContent": "use of general anaesthesia (suspend metformin on the morning of surgery and restart when renal function returns to baseline)",
                "html": "use of general anaesthesia (suspend metformin on the morning of surgery and restart when renal function returns to baseline)"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Iodine-containing X-ray contrast media",
                "textContent": "Intravascular administration of iodinated contrast agents can cause renal failure, which can increase the risk of lactic acidosis with metformin. Suspend metformin prior to the test; restart no earlier than 48 hours after the test if renal function has returned to baseline.",
                "html": "<p>Intravascular administration of iodinated contrast agents can cause renal failure, which can increase the risk of lactic acidosis with metformin. Suspend metformin prior to the test; restart no earlier than 48 hours after the test if renal function has returned to baseline.</p>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Can provoke lactic acidosis",
                "html": "Can provoke lactic acidosis"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (antidiabetics).",
                "html": "<p>Appendix 1 (antidiabetics).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "anorexia",
                        "html": "anorexia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea (usually transient)",
                        "html": "diarrhoea (usually transient)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "taste disturbance",
                        "html": "taste disturbance",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Decreased vitamin-B12 absorption",
                        "html": "Decreased vitamin-B<sub>12</sub> absorption",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "erythema",
                        "html": "erythema",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "lactic acidosis (withdraw treatment)",
                        "html": "lactic acidosis (withdraw treatment)",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "urticaria",
                        "html": "urticaria",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Hepatitis",
                        "html": "Hepatitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Gastro-intestinal effects",
                "textContent": "Gastro-intestinal side-effects are initially common with metformin, and may persist in some patients, particularly when very high doses are given. A slow increase in dose may improve tolerability.",
                "html": "<p>Gastro-intestinal side-effects are initially common with metformin, and may persist in some patients, particularly when very high doses are given. A slow increase in dose may improve tolerability.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Can be used in pregnancy for both pre-existing and gestational diabetes. Women with gestational diabetes should discontinue treatment after giving birth.",
                "html": "<p>Can be used in pregnancy for both pre-existing and gestational diabetes. Women with gestational diabetes should discontinue treatment after giving birth.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "May be used during breast-feeding in women with pre-existing diabetes.",
                "html": "<p>May be used during breast-feeding in women with pre-existing diabetes.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Withdraw if tissue hypoxia likely.",
                "html": "<p>Withdraw if tissue hypoxia likely.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use with caution in renal impairment&#8212; increased risk of lactic acidosis.\n\nLactic acidosis Withdraw or interrupt treatment in those at risk of tissue hypoxia or sudden deterioration in renal function, such as those with dehydration, severe infection, shock, sepsis, acute heart failure, respiratory failure or hepatic impairment, or those who have recently had a myocardial infarction.",
                "html": "<p>Use with caution in renal impairment&#8212; increased risk of lactic acidosis.</p><p outputclass=\"title\">Lactic acidosis</p> <p>Withdraw or interrupt treatment in those at risk of tissue hypoxia or sudden deterioration in renal function, such as those with dehydration, severe infection, shock, sepsis, acute heart failure, respiratory failure or hepatic impairment, or those who have recently had a myocardial infarction.</p>"
            },
            {
                "type": "generalInformation",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "textContent": "NICE (clinical guideline 87 (May 2009): Type 2 diabetes: The management of type 2 diabetes) recommends that the dose should be reviewed if eGFR less than 45 mL/minute/1.73 m2 and to avoid if eGFR less than 30 mL/minute/1.73 m2.",
                "html": "<p>NICE (clinical guideline 87 (May 2009): Type 2 diabetes: The management of type 2 diabetes) recommends that the dose should be reviewed if eGFR less than 45&#8239;mL/minute/1.73&#8239;m<sup>2</sup> and to avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            },
            {
                "type": "generalInformation",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "Avoid in significant renal impairment.",
                "html": "<p>Avoid in significant renal impairment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Determine renal function before treatment and at least annually (at least twice a year in patients with additional risk factors for renal impairment, or if deterioration suspected).",
                "html": "<p>Determine renal function before treatment and at least annually (at least twice a year in patients with additional risk factors for renal impairment, or if deterioration suspected).</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "textContent": "Patients taking up to 2 g daily of the standard-release metformin may start with the same daily dose of metformin modified release; not suitable if dose of standard-release tablets more than 2 g daily.",
                "html": "<p>Patients taking up to 2&#8239;g daily of the standard-release metformin may start with the same daily dose of metformin modified release; not suitable if dose of standard-release tablets more than 2&#8239;g daily.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "references": [
                    {
                        "id": "http://www.medicinesforchildren.org.uk/metformin-diabetes",
                        "label": "www.medicinesforchildren.org.uk/metformin-diabetes"
                    }
                ],
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "title": "Medicines for Children leaflet: Metformin for diabetes",
                "textContent": "www.medicinesforchildren.org.uk/metformin-diabetes",
                "html": "<p>\n<xref format=\"html\" href=\"http://www.medicinesforchildren.org.uk/metformin-diabetes\">www.medicinesforchildren.org.uk/metformin-diabetes</xref>\n</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension",
                "oral solution",
                "capsule"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76109",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76129",
                "label": "Modified-release tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76123",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76135",
                "label": "Powder",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP101223",
                "label": "CANAGLIFLOZIN WITH METFORMIN",
                "type": "drug"
            },
            {
                "id": "PHP85567",
                "label": "ALOGLIPTIN WITH METFORMIN",
                "type": "drug"
            },
            {
                "id": "PHP85589",
                "label": "DAPAGLIFLOZIN WITH METFORMIN",
                "type": "drug"
            },
            {
                "id": "PHP85624",
                "label": "LINAGLIPTIN WITH METFORMIN",
                "type": "drug"
            },
            {
                "id": "PHP85626",
                "label": "METFORMIN WITH PIOGLITAZONE",
                "type": "drug"
            },
            {
                "id": "PHP85627",
                "label": "METFORMIN WITH SAXAGLIPTIN",
                "type": "drug"
            },
            {
                "id": "PHP85628",
                "label": "METFORMIN WITH SITAGLIPTIN",
                "type": "drug"
            },
            {
                "id": "PHP85629",
                "label": "METFORMIN WITH VILDAGLIPTIN",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP97237",
                "label": "Adverse reactions to drugs",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78083",
                "label": "Scalp and hair conditions",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78107",
                "label": "Insulins and anti-diabetic drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_267",
                "label": "Metformin",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76109",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76129",
                "label": "Modified-release tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76123",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76135",
                "label": "Powder",
                "type": "medicinalForm"
            }
        ]
    }
}